The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmac
The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Plovamer acetate
HLA class II histocompatibility antigen, DRB1-15 beta chain modulator
What it measured
Main measures
Safety parameters :
Safety
Who could take part
Progressive MS
Show the full criteria
Inclusion criteria
Inclusion: 1. Male or female subjects between the ages of 18 and 60 (inclusive) who have signed an approved, informed consent document. Exclusion: 1. Currently or within the past 5 years, history of malignancy other than squamous or basal cell carcinoma of the skin.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary objective of this study is to evaluate the safety and tolerability of 4 to 6 dose levels of PI 2301 in subjects with SP-MS when administered weekly for up to 12 weeks
Loading reviews and guidelines…
Related trials
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cel
Phase 1 / Phase 2 · Not yet recruiting
Still running
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) fo
Phase 2 · Not yet recruiting
Still running
- Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis
Phase 2 · Not yet recruiting
Still running
- Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
Phase 1 · Recruiting
Still running
- Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Tre
Phase 1 · Recruiting
Still running
- Nasal Foralumab in Patients With Non-Active Secondary Progressive Mult
Phase 2 · Recruiting
Still running
History
Started
Aug 2008